

CURRENT REPORT 12K/2024

March 7, 2024

Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow (the "Company"), hereby submits the correction of obvious typographical error identified in the Polish version of current report No. 12/2024 dated March 6, 2024, regarding the deadline by which the Company is obliged to repay the first tranche of financing received from the European Investment Bank. The date indicated as March 13, 2023, has been identified as erroneous, whereas the correct date is March 13, 2029. The remaining content of the Company's current report No. 12/2024 remains unchanged.

Therefore, the content of the current report No. 12/2024 dated March 6, 2024, is as follows:

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow („**Company**”), with reference to current reports no. 14/2022 of 17 August 2022, no. 19/2023 of 5 May 2023, no. 33/2023 of 19 June 2023, no. 2/2024 of 17 January 2024, and no. 4/2023 of 30 January 2024, hereby informs that, on 5 March, 2024, the Company received from the European Investment Bank ("**EBI**") confirmation that the Company has fulfilled all conditions for the disbursement of the first tranche of financing ("**Tranche A**") under the financing agreement concluded on 16 August 2022. As a result, the Company expects to receive on March 13, 2024 an amount of EUR 8,000,000.00 (34,582,400.00 PLN converted at the average exchange rate of the National Bank of Poland on March 5, 2024, 1 EUR = 4.3228 PLN). The Company is obligated to repay Tranche A by 13 March, 2029.

After the disbursement of Tranche A, EBI will be entitled to:

- (i) convert 215.575 subscription warrants (constituting 36,364% of all the 592.825 subscription warrants held by EBI) into 215.575 ordinary bearer shares of series K of the Company,
- (ii) dispose the subscription warrants,
- (iii) require from the Company the purchase of the subscription warrants for their cancellation,

all in accordance with the terms specified in the subscription warrant issuance agreement concluded on 4 May 2023.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board